Why we need epidemiologic studies of polycystic ovary syndrome in Africa

Maya, Ernest; Guure, Chris; Adanu, Richard; Sarfo, Bismark; Ntumy, Michael; Bonney, Evelyn Yayra; Lizneva, Daria; Walker, Walidah; Azziz, Ricardo

doi:10.1002/ijgo.12642

Cited by 7 publications

(4 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With prevalence ranging between 5-15%, PCOS remains a multifactorial disorder that still requires extensive research in management techniques and how it affects bodily functions widely 1 . A higher prevalence of PCOS is seen in Mexican-Americans than non-Hispanic whites and African Americans 2 . The diagnosis of PCOS is usually clinical and based on the exclusion of other disorders.…”

Section: Introductionmentioning

confidence: 94%

Novel Antidiabetic Medications in Polycystic Ovary Syndrome

Somagutta¹,

Jain²,

Uday³

et al. 2022

Discoveries

View full text Add to dashboard Cite

Polycystic ovary syndrome is a very common endocrine disorder prevalent in premenopausal women. Patients with polycystic ovary syndrome present with abnormal menstruation, ovulation disorders, and hyperandrogenemia. They are often accompanied by insulin resistance, metabolic disorders, and other cardiovascular abnormalities. Also, they have comorbidities, such as dyslipidemia, obesity, diabetes type 2, non-alcoholic fatty liver disease, which all influence the treatment plan. Metformin has been defined as a treatment option in patients with polycystic ovary syndrome. However, the clinical responses to metformin are limited. Thus, the need for novel treatments with a broad range of coverage for the complications is warranted. Sodium-glucose co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists, incretin analogs are novel drugs approved for treating type-2 diabetes. Because of their recorded benefit with weight loss, improved insulin resistance, and cardiovascular benefits in recent studies, they may help polycystic ovary syndrome women address the polycystic ovary syndrome-related risk of metabolic, reproductive, and psychological consequences. Limited literature is available on the safety and efficacy of these novel antidiabetic drugs in patients with polycystic ovary syndrome. Thus, this review is investigating the role and effectiveness of novel antidiabetic medication as an early therapeutic option in polycystic ovary syndrome.

show abstract

Section: Introductionmentioning

confidence: 94%

Novel Antidiabetic Medications in Polycystic Ovary Syndrome

Somagutta¹,

Jain²,

Uday³

et al. 2022

Discoveries

View full text Add to dashboard Cite

show abstract

“…Higher prevalence has been associated in first-degree relatives with PCOS, prepubertal obesity, congenital virilizing disorders, above average or low birth weight for gestational age, premature adrenarche, use of valproic acid as an antiepileptic drug. Studies have also suggested that there is a higher prevalence in Mexican-Americans than non-Hispanic whites and African Americans [6,7] .…”

Section: Etiologymentioning

confidence: 99%

Betatrophin in polycystic ovary disease and its association with insulin resistance

Saeed¹,

F.Abbas²

2021

Int. J. Clin. Obstet. Gynaecol.

View full text Add to dashboard Cite

Background: Betatrophin, a newly identified peptide hormone secreted mainly by liver and adipose tissue, is a member of a family of angiopoietin-like proteins and is implicated in the regulation of lipid and glucose metabolism. Originally, betatrophin was determined to function in lipid metabolism by reducing triglyceride clearance through lipoprotein lipase inhibition. Objective: To assess the association between Betatrophin and insulin resistance in polycystic ovary disease women. Patients and Method: A case control study carried in our hospital, at the period from the 1 st of October 2019 to the end of January 2020. One hundred women were enrolled in the current study and divided into 2 groups. Results: S. Betatrophin levels were significantly higher increases in case group (PCOS patients) than that in control group (P<0.001). The correlation analysis between serum Betatrophin and various parameters in table 4 showed that there is a positive correlation between circulating Betatrophin levels with fasting insulin, and HOMA-IR. While negative correlation found with fasting blood glucose. Conclusion: Betatrophin highly significantly increase in PCOS patients, and betatrophin is independently associated with insulin resistance.

show abstract

“…But while these data are accumulating in different populations, data on this issue are lacking on sub-Saharan African populations. Therefore, studies are needed to provide data on this topic on a population where metabolic disorders are highly prevalent [ 15 ]. In this light, we aimed to study the levels of adiponectin in cameroonian women living with PCOS.…”

Section: Introductionmentioning

confidence: 99%

Adiponectin levels and its relation with insulin secretion and insulin sensitivity in a group of sub-Saharan African women with polycystic ovary syndrome

et al. 2022

View full text Add to dashboard Cite

Objectives Low levels of adiponectin have been reported in Polycystic Ovary Syndrome (PCOS). In sub-Saharan Africa, little data are available on the topic. We aimed to investigate the levels of adiponectin and its relation with insulin secretion and insulin sensitivity in women with PCOS in Yaoundé, Cameroon. A comparative cross-sectional study was conducted in 32 women presenting PCOS and 32 controls matched for age and Body Mass Index. For each participant, adiponectin levels were measured. We estimated insulin sensitivity using Homeostasis model index (HOMA-IR) and insulin secretion with C-peptide levels. Results Women with PCOS had higher insulin secretion levels than controls (C-peptide: 4.98 ± 3.83 vs 3.25 ± 1.62 mUI/l; p = 0.02). Also, the HOMA-IR index was higher compared to that of women without PCOS (1.15 ± 0.90 vs 0.77 ± 0.38; p = 0.03) suggesting greater insulin resistance. The median [25th–75th percentile] values of adiponectin concentrations were similar between the two groups (22.68 [21.72–23.41] μg/ml vs 22.03 [21.40–22.93] μg/ml; p = 0.1). There was no association between insulin sensitivity and adiponectin levels in the PCOS group. PCOS is not associated with changes in adiponectin in a population of sub-Saharan African women. Further studies are needed to shed more light on this condition.

show abstract

Why we need epidemiologic studies of polycystic ovary syndrome in Africa

Cited by 7 publications

References 27 publications

Novel Antidiabetic Medications in Polycystic Ovary Syndrome

Novel Antidiabetic Medications in Polycystic Ovary Syndrome

Betatrophin in polycystic ovary disease and its association with insulin resistance

Adiponectin levels and its relation with insulin secretion and insulin sensitivity in a group of sub-Saharan African women with polycystic ovary syndrome

Contact Info

Product

Resources

About